Search Results

Your search for Ibiayi Dagogo-Jack, MD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / August 25, 2025

ASCO Names 2025 Q1, Q2 FASCO Recipients

Launched in 2007 and formerly called the ASCO Statesman Award, the FASCO distinction honors members for their extraordinary volunteer service, engagement, and dedication to American Society of Clinical Oncology and the Association for Clinical Oncology (collectively ASCO). Listed here are the FASCO ...

lung cancer

genomics/genetics

immunotherapy

By Ibiayi Dagogo-Jack, MD / May 10, 2022

DESTINY-Lung01: Is Trastuzumab Deruxtecan the Answer for HER2-Mutant Lung Cancer?

The human epidermal growth factor (HER) family of receptors are a well-established therapeutic target. Indeed, seminal studies conducted nearly 2 decades ago identified a key association between activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR, also known as...

Sep

Today In Oncology

Search Results

Your search for Ibiayi Dagogo-Jack, MD matches 2 pages

ASCO Names 2025 Q1, Q2 FASCO Recipients

DESTINY-Lung01: Is Trastuzumab Deruxtecan the Answer for HER2-Mutant Lung Cancer?

Novel ADC Under Study in Previously Treated EGFR-Mutated NSCLC

New Subcutaneous Amivantamab Combo Dosing Schedule Shows Safety and Efficacy in EGFR-Positive NSCLC

STAS Predicts Prognosis in Early NSCLC Regardless of Surgical Approach

Hypofractionated vs Conventional Radiotherapy in Phase III Trial for LS-SCLC

Tarlatamab and Anti-PD-1 Therapy as First-Line Maintenance for ES-SCLC